AstraZeneca Reports P-III (DELIVER) Trial Results of Farxiga (dapagliflozin) for Heart Failure Associated with Mildly Reduced or Preserved Ejection Fraction
Shots:
- The P-III (DELIVER) trial evaluating Farxiga (qd) + SoC vs PBO in 6263 patients with HF with LVEF ≥40% with/out T2D
- The results showed an improvement in symptom burden and health-related QoL in patients with HF and mildly reduced or preserved EF, clinical benefits were observed, and benefits were sustained @8mos. with a mean improvement in total symptom score. The results were presented at AHA 2022 & published in the JACC
- Patients achieved a significant deterioration, improvements in health status across evaluated KCCQ domains, and benefits of Farxiga on CV death & worsening HF. The safety & tolerability profiles were consistent with the well-established safety profile of the therapy
Ref: AstraZeneca | Image: AstraZeneca
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
